Infection Control
RSSArticles
-
APIC 2023 Keynote: IPs Must Reclaim Their Power
The 2023 APIC keynote speaker called for infection preventionists to reclaim their narrative, to tell people what they do in no uncertain terms, and to empower others to do likewise.
-
Biden Announces Choice for New CDC Director
Mandy Cohen will succeed Rochelle Walensky, who will step down at the end of June.
-
Scientists Use Artificial Intelligence While Searching for ‘Superbug’ Solutions
Researchers enlisted the help of technology to find an antibiotic that could fight multidrug-resistant bacteria.
-
Respiratory Syncytial Virus Vaccine, Adjuvanted (Arexvy)
Arexvy can be administered to prevent lower respiratory tract disease caused by respiratory syncytial virus in patients age 60 years and older.
-
RSV Vaccine for Older Patients Receives Support
FDA approved Arexvy to protect people age 60 years and older against the respiratory syncytial virus.
-
Healthcare Workers Not Likely Infected, Colonized with C. auris
Recent reports highlighting the continuing increase and geographic spread of Candida auris — a multidrug-resistant fungus that is moving between healthcare facilities — have raised the question of whether healthcare workers could be infected or colonized with the emerging pathogen. It is highly unlikely, but the risk is not zero.
-
CDC: Be Wary of Travelers From African Outbreaks
Marburg virus has caused outbreaks in two African nations, and healthcare workers should be aware of travel history for incoming patients with classic hemorrhagic fever symptoms.
-
First Oral Fecal Microbiota Product Wins FDA Approval
There is a new tool available in the battle against one of the most common healthcare-associated infections in the United States.
-
Researchers Use Advanced Technology to Detect MIS-C
Scientists want to improve diagnostic techniques for multisystem inflammatory syndrome in children, which became a confounding problem during the COVID-19 pandemic.
-
Rezafungin Injection (Rezzayo)
Rezafungin can be prescribed to treat candidemia and invasive candidiasis in patients age 18 years or older with limited or no alternative options.